GPC3, of heparan sulfate (HS) proteoglycans family, is noted to be prominent in HCC and considered to be an active target in HCC treatments (Zhang et al., 2012; Baumhoer et al., 2008; Yamauchi et al., 2005). This evidence concerns the gene GPC3 and hepatocellular carcinoma.